Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: A case report and literature review

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 2767-2770

  Chen, Dawei ^a,b   Zhang, Yan ^b   Shi, Fang ^b   Li, Minghuan ^b   Zhu, Hui ^b   Kong, Li ^b   Yu, Jinming ^b  

^a WEIFANG MEDICAL UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Bevacizumab; Lung cancer; Malignant pericardial effusion

Indexed keywords

BEVACIZUMAB; CISPLATIN; ERLOTINIB; PEMETREXED;

ADULT; ARTICLE; ASTHMA; BONE METASTASIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; ECHOGRAPHY; FEMALE; HEART PALPITATION; HOSPITAL ADMISSION; HUMAN; LEG EDEMA; LUNG ADENOCARCINOMA; MALIGNANT PERICARDIAL EFFUSION; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICARDIAL EFFUSION; PLEURA EFFUSION;

EID: 84943369737     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S90145     Document Type: Article

References (17)

1. McAllister HA Jr, Hall RJ, Cooley DA. Tumors of the heart and pericardium. Curr Probl Cardiol. 1999;24(2):57–116.
2. Jama GM, Scarci M, Bowden J, Marciniak SJ. Palliative treatment for symptomatic malignant pericardial effusion. Interact Cardiovasc Thorac Surg. 2014;19(6):1019–1026.
3. Klatt EC, Heitz DR. Cardiac metastases. Cancer. 1990;65(6):1456–1459.
4. Skhvatsabaja LV. Secondary malignant lesions of the heart and pericardium in neoplastic disease. Oncology. 1986;43(2):103–106.
5. Martinoni A, Cipolla CM, Civelli M, et al. Intrapericardial treatment of neoplastic pericardial effusion. Herz. 2000;25(8):787–793.
6. Oida T, Mimatsu K, Kano H, et al. Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade. World J Gastroenterol. 2010;16(6):740–744.
7. Chen LK, Xu GC, Liang Y, Yang QY, Zhang LN. [Intrapericardial infusion of etoposide and cisplatin in treating malignant pericardial effusion of non-small cell lung cancer]. Ai Zheng. 2006;25(4):505–508. Chinese.
8. Millaire A, Wurtz A, Brullard B, et al. [Value of pericardioscopy in patients with pericardial effusion. A propos of 20 patients]. Arch Mal Coeur Vaiss. 1988;81(9):1071–1076. French.
9. Zhou WB, Bai M, Jin Y. Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions. Int J Tuberc Lung Dis. 2009;13(3):381–386.
10. Nagy JA, Dvorak AM, Dvorak HF. Vascular hyperpermeability, angiogenesis, and stroma generation. Cold Spring Harb Perspect Med. 2012;2(2):a006544.
11. Sriram KB, Relan V, Clarke BE, et al. Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncol. 2011;7(6):737–752.
12. Midgley R, Kerr D. Bevacizumab–current status and future directions. Ann Oncol. 2005;16(7):999–1004.
13. Ribeiro SC, Vargas FS, Antonangelo L, et al. Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion. Respirology. 2009;14(8):1188–1193.
14. Luo JC, Yamaguchi S, Shinkai A, Shitara K, Shibuya M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res. 1998;58(12):2652–2660.
15. El-Shami K, Elsaid A, El-Kerm Y. Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J Clin Oncol. 2007;25(18 Suppl):9043.
16. Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol. 2006;102(3):425–428.
17. Du N, Li X, Li F, et al. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion. Oncol Rep. 2013;29(6):2332–2340.